Century Therapeutics, Inc.
3675 Market Street, Suite 200
Philadelphia
PA
19104
United States
Website: https://www.centurytx.com/contact-us/
About Century Therapeutics, Inc.
At Century, we are harnessing the power of adult stem cells to develop best-in-class allogeneic iNK and iT cell therapies for cancer. Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies with significant unmet medical need. To achieve our mission, we are recruiting talented employees with diverse skills and subject matter expertise in order to achieve our scientific and business goals.
Together, we can change the future of cancer care by developing novel curative therapies for patients in need. We are One Century.
Offices in:
• Philadelphia, PA – Corporate Headquarters
• Branchburg, NJ – Our new facility to support the development of novel allogeneic living drugs for oncology treatment
COMPANY MISSION & VALUES
We are “One Century” and we’re on an important journey together to transform the future of cancer treatment. In pursuit of our mission, we firmly adhere to and are driven by our values.
• Integrity
• Passion
• Science
• Courage
CENTURY AT WORK, CENTURY AT PLAY
We believe in balance. We work hard every day to advance innovative immune cell therapies to meet the critical needs of the patients we aim to serve. Our work is driven by revolutionary ideas – not titles – and we value contributions from all. We have assembled a highly productive team that enjoys rigorous innovation and spending time together. If this sounds like an environment in which you would thrive, click the link below to view our current openings.
Stock Exchange: NASDAQ
Stock Symbol: IPSC
CONNECT
Century Therapeutics Inc. is an Equal Employment Opportunity/Affirmative Action Employer - Minority/Female/Disability/Veteran. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, or veteran status or any other characteristic protected by federal, state, or local law. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.
56 articles about Century Therapeutics, Inc.
-
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
4/17/2023
Century Therapeutics announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.
-
Century Therapeutics Announces Leadership Changes
4/12/2023
Century Therapeutics today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023.
-
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
3/16/2023
Century Therapeutics, Inc. today reported financial results and business highlights for the full-year ended December 31, 2022.
-
Century Therapeutics to Present at the AACR Annual Meeting 2023
3/15/2023
Century Therapeutics announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research Annual Meeting on Monday, April 17, 2023.
-
Century Therapeutics to Present at Upcoming Investor Conferences - February 21, 2023
2/21/2023
Century Therapeutics, an innovative clinical-stage biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the management team will participate in the following investor conferences.
-
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
2/8/2023
Century Therapeutics, Inc. announced today that the first patient has been dosed in the first-in-human Phase 1 ELiPSE-1 trial evaluating CNTY-101 in patients with relapsed or refractory CD19 positive B-cell lymphomas.
-
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
1/5/2023
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026.
-
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Century Therapeutics today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT.
-
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Century Therapeutics today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 2:00 PM ET.
-
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
11/11/2022
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced preclinical data from the Company’s iPSC-based cell therapy platform were featured in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/10/2022
Century Therapeutics today reported financial results and business highlights for the third quarter ended September 30, 2022.
-
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
11/2/2022
Century Therapeutics today announced that it will host a virtual Research and Development (R&D) Day on Friday, November 11, 2022, from 8:00 AM to 9:30 AM ET.
-
Century Therapeutics to Present at the SITC 37th Annual Meeting
10/5/2022
Century Therapeutics today announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, on November 8-12, 2022 in Boston, Massachusetts.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
8/25/2022
Century Therapeutics, Inc. announced today that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.
-
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/11/2022
Century Therapeutics , Inc. today reported financial results and business highlights for the second quarter ended June 30, 2022.
-
Century Therapeutics Announces Its Addition to the Russell Microcap® Index
6/24/2022
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.
-
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
6/21/2022
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET.
-
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
6/6/2022
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that it will host a virtual Research and Development Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET.
-
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
5/16/2022
Century Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.